TOOTH (The Open study Of dental pulp stem cell Therapy in Humans): Study protocol for evaluating safety and feasibility of autologous human adult dental pulp stem cell therapy in patients with chronic disability after stroke

Abstract

Rationale

Stroke represents a significant global disease burden. As of 2015, there is no chemical or biological therapy proven to actively enhance neurological recovery during the chronic phase post-stroke. Globally, cell-based therapy in stroke is at the stage of clinical translation and may improve neurological function through various mechanisms such as neural replacement, neuroprotection, angiogenesis, immuno-modulation, and neuroplasticity. Preclinical evidence in a rodent model of middle cerebral artery ischemic stroke as reported in four independent studies indicates improvement in neurobehavioral function with adult human dental pulp stem cell therapy. Human adult dental pulp stem cells present an exciting potential therapeutic option for improving post-stroke disability.

Aims

TOOTH (The Open study Of dental pulp stem cell Therapy in Humans) will investigate the use of autologous stem cell therapy for stroke survivors with chronic disability, with the following objectives: (a) determine the maximum tolerable dose of autologous dental pulp stem cell therapy; (b) define that dental pulp stem cell therapy at the maximum tolerable dose is safe and feasible in chronic stroke; and (c) estimate the parameters of efficacy required to design a future Phase 2/3 clinical trial.

Methods and design

TOOTH is a Phase 1, open-label, single-blinded clinical trial with a pragmatic design that comprises three stages: Stage 1 will involve the selection of 27 participants with middle cerebral artery ischemic stroke and the commencement of autologous dental pulp stem cell isolation, growth, and testing in sequential cohorts (n = 3). Stage 2 will involve the transplantation of dental pulp stem cell in each cohort of participants with an ascending dose and subsequent observation for a 6-month period for any dental pulp stem cell-related adverse events. Stage 3 will investigate the neurosurgical intervention of the maximum tolerable dose of autologous dental pulp stem cell followed by 9 weeks of intensive task-specific rehabilitation. Advanced magnetic resonance and positron emission tomography neuro-imaging, and clinical assessment will be employed to probe any change afforded by stem cell therapy in combination with rehabilitation.

Sample size estimates

Nine participants will step-wise progress in Stage 2 to a dose of up to 10 million dental pulp stem cell, employing a cumulative 3 + 3 statistical design with low starting stem cell dose and subsequent dose escalation, assuming that an acceptable probability of dose-limiting complications is between 1 in 6 (17%) and 1 in 3 (33%) of patients. In Stage 3, another 18 participants will receive an intracranial injection with the maximum tolerable dose of dental pulp stem cell.

Outcomes

The primary outcomes to be measured are safety and feasibility of intracranial administration of autologous human adult DPSC in patients with chronic stroke and determination of the maximum tolerable dose in human subjects. Secondary outcomes include estimation of the measures of effectiveness required to design a future Phase 2/3 clinical trial.

Keywords

Ischemic stroke adult human dental pulp stem cells post stroke disability neurobehavioral outcomes

Get full access to this article

View all access options for this article.

References

Feigin

Forouzanfar

Krishnamurthi

Mensah

Connor

Bennett

et al.

Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245–254.

Leyden

Kleinig

Newbury

Castle

Cranefield

Anderson

et al.

Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke 2013; 44: 1226–1231.

Jauch

Saver

Adams

Jr Bruno

Connors

Demaerschalk

et al.

Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870–947.

Billinger

Arena

Bernhardt

Eng

Franklin

Johnson

et al.

Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2532–2553.

Carey LM (ed). Stroke rehabilitation: insights from neuroscience and imaging. Oxford, UK: Oxford University Press, 2012. ISBN 978-0-19-979788-2.

Mead

Hsieh

Lee

Kutlubaev

Claxton

Hankey

et al.

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2012; 11: CD009286.

Lindvall

Kokaia

. Stem cells for the treatment of neurological disorders. Nature 2006; 441: 1094–1096.

Aboody

Capela

Niazi

Stern

Temple

. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron 2011; 70: 597–613.

Leong

Lewis

Koblar

. Concise review: Preclinical studies on human cell-based therapy in rodent ischemic stroke models: where are we now after a decade? Stem Cells 2013; 31: 1040–1043.

10.

Leong

Henshall

Arthur

Kremer

Lewis

Helps

et al.

Human adult dental pulp stem cells enhance poststroke functional recovery through non-neural replacement mechanisms. Stem Cells Transl Med 2012; 1: 177–187.

11.

Chopp

. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002; 1: 92–100.

12.

Martino

Pluchino

. The therapeutic potential of neural stem cells. Nat Rev Neurosci 2006; 7: 395–406.

13.

Andres

Horie

Slikker

Keren-Gill

Zhan

Sun

et al.

Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain 2011; 134(Pt 6): 1777–1789.

14.

Lemmens

Steinberg

. Stem cell therapy for acute cerebral injury: what do we know and what will the future bring? Curr Opin Neurol 2013; 26: 617–625.

15.

Prockop

Brenner

Fibbe

Horwitz

Le Blanc

Phinney

et al.

Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12: 576–578.

16.

Lees

Sena

Egan

Antonic

Koblar

Howells

et al.

Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis. Int J Stroke 2012; 7: 582–588.

17.

Savitz

. Developing cellular therapies for stroke. Stroke 2015; 46: 2026–2031.

18.

Kalladka

Muir

. Brain repair: cell therapy in stroke. Stem Cells Cloning 2014; 7: 31–44.

19.

Kondziolka

Steinberg

Wechsler

Meltzer

Elder

Gebel

et al.

Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg 2005; 103: 38–45.

20.

Bhasin

Srivastava

Mohanty

Bhatia

Kumaran

Bose

. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg 2013; 115: 1003–1008.

21.

Bhasin

Srivastava

Bhatia

Mohanty

Kumaran

Bose

. Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J Stem Cells Regen Med 2012; 8: 181–189.

22.

Bhasin

Srivastava

Kumaran

Mohanty

Bhatia

Bose

et al.

Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra 2011; 1: 93–104.

23.

Rabinovich

Seledtsov

Banul

Poveshchenko

Senyukov

Astrakov

et al.

Cell therapy of brain stroke. Bull Exp Biol Med 2005; 139: 126–128.

24.

Kondziolka

Wechsler

Goldstein

Meltzer

Thulborn

Gebel

et al.

Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000; 55: 565–569.

25.

Savitz

Dinsmore

Henderson

Stieg

Caplan

. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis 2005; 20: 101–107.

26.

Friedrich

Martins

Araujo

Klamt

Vedolin

Garicochea

et al.

Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant 2012; 21(Suppl 1): S13–S21.

27.

Moniche

Escudero

Zapata-Arriaza

Usero-Ruiz

Prieto-Leon

de la Torre

et al.

Intra-arterial bone marrow mononuclear cells (BM-MNCs) transplantation in acute ischemic stroke (IBIS trial): protocol of a phase II, randomized, dose-finding, controlled multicenter trial. Int J Stroke 2015; 10: 1149–1152.

28.

Moniche

Gonzalez

Gonzalez-Marcos

Carmona

Pinero

Espigado

et al.

Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke 2012; 43: 2242–2244.

29.

Mendonca

Freitas

Silva

Manfrim

Falcao

Gonzales

et al.

[Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke]. Arq Bras Cardiol 2006; 86: 52–55.

30.

Battistella

de Freitas

da Fonseca

LMB

Mercante

Gutfilen

Goldenberg

et al.

Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med 2011; 6: 45–52.

31.

Suarez-Monteagudo

Hernandez-Ramirez

Alvarez-Gonzalez

Garcia-Maeso

de la Cuetara-Bernal

Castillo-Diaz

et al.

Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor Neurol Neurosci 2009; 27: 151–161.

32.

Honmou

Houkin

Matsunaga

Niitsu

Ishiai

Onodera

et al.

Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011; 134(Pt 6): 1790–1807.

33.

Chen

Lin

Fan

Lin

Lee

Lin

et al.

Intracerebral implantation of autologous peripheral blood stem cells in stroke patients: a randomized phase II study. Cell Transplant 2014; 23: 1599–1612.

34.

Lee

Hong

Moon

Lee

Ahn

Bang

. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010; 28: 1099–1106.

35.

Bang

Lee

. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874–882.

36.

Prasad

Sharma

Garg

Mohanty

Bhatnagar

Johri

et al.

Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke 2014; 45: 3618–3624.

37.

Prasad

Mohanty

Bhatia

Srivastava

Garg

Srivastava

et al.

Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res 2012; 136: 221–228.

38.

Savitz

Misra

Kasam

Juneja

Cox

Jr Alderman

et al.

Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol 2011; 70: 59–69.

39.

Yang

Rosenberg

. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011; 42: 3323–3328.

40.

Iadecola

Anrather

. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17: 796–808.

41.

Gronthos

Mankani

Brahim

Robey

Shi

. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 2000; 97: 13625–13630.

42.

Kaukua

Shahidi

Konstantinidou

Dyachuk

Kaucka

Furlan

et al.

Glial origin of mesenchymal stem cells in a tooth model system. Nature 2014; 513: 551–554.

43.

Arthur

Rychkov

Shi

Koblar

Gronthos

. Adult human dental pulp stem cells differentiate toward functionally active neurons under appropriate environmental cues. Stem Cells 2008; 26: 1787–1795.

44.

Neirinckx

Coste

Rogister

Wislet-Gendebien

. Concise review: adult mesenchymal stem cells, adult neural crest stem cells, and therapy of neurological pathologies: a state of play. Stem Cells Transl Med 2013; 2: 284–296.

45.

Kiraly

Porcsalmy

Pataki

Kadar

Jelitai

Molnar

et al.

Simultaneous PKC and cAMP activation induces differentiation of human dental pulp stem cells into functionally active neurons. Neurochem Int 2009; 55: 323–332.

46.

Arthur

Shi

Zannettino

Fujii

Gronthos

Koblar

. Implanted adult human dental pulp stem cells induce endogenous axon guidance. Stem Cells 2009; 27: 2229–2237.

47.

Yang

Chen

Liao

Pang

Lin

. A simple and efficient method for generating Nurr1-positive neuronal stem cells from human wisdom teeth (tNSC) and the potential of tNSC for stroke therapy. Cytotherapy 2009; 11: 606–617.

48.

Sugiyama

Iohara

Wakita

Hattori

Ueda

Matsushita

et al.

Dental pulp-derived CD31(-)/CD146(-) side population stem/progenitor cells enhance recovery of focal cerebral ischemia in rats. Tissue Eng Part A 2011; 17: 1303–1311.

49.

Inoue

Sugiyama

Hattori

Wakita

Wakabayashi

Ueda

. Stem cells from human exfoliated deciduous tooth-derived conditioned medium enhance recovery of focal cerebral ischemia in rats. Tissue Eng Part A 2013; 19: 24–29.

50.

d'Aquino

De Rosa

Lanza

Tirino

Laino

Graziano

et al.

Human mandible bone defect repair by the grafting of dental pulp stem/progenitor cells and collagen sponge biocomplexes. Eur Cell Mater 2009; 18: 75–83.

51.

ClinicalTrials.gov Identifier: NCT01814436. Shi, S. Principal Investigator. Revitalization of Immature Permanent Teeth With Necrotic Pulps Using SHED Cells. Available at: https://clinicaltrials.gov/ct2/show/NCT01814436?term=NCT01814436&rank=1 (accessed 14 October 2015).

52.

Rose

Worrall

Hickson

Hoffmann

. Aphasia friendly written health information: content and design characteristics. Int J Speech Lang Pathol 2011; 13: 335–347.

53.

Braunack-Mayer

Hersh

. An ethical voice in the silence of aphasia: judging understanding and consent in people with aphasia. J Clin Ethics 2001; 12: 388–396.

54.

Kertesz A. Western aphasia battery test manual. Psychological Corp, United States: Harcourt Brace Jovanovich Inc., 1982.

55.

Raven J. Raven progressive matrices. Handbook of nonverbal assessment. Springer, 2003, pp.223–337. US. ISBN 978-1-4615-0153-4.

56.

Bennett

Thomas

Austen

Morris

AMS

Lincoln

. Validation of screening measures for assessing mood in stroke patients. Br J Clin Psychol 2006; 45: 367–376.

57.

Suchankova Kleplova

Soukup

Rehacek

Suchanek

. Human plasma and human platelet-rich plasma as a substitute for fetal calf serum during long-term cultivation of mesenchymal dental pulp stem cells. Acta Med (Hradec Kralove) 2014; 57: 119–126.

58.

Shi

Robey

Gronthos

. Comparison of human dental pulp and bone marrow stromal stem cells by cDNA microarray analysis. Bone 2001; 29: 532–539.

59.

Eleuterio

Trubiani

Sulpizio

Di Giuseppe

Pierdomenico

Marchisio

et al.

Proteome of human stem cells from periodontal ligament and dental pulp. PLoS One 2013; 8: e71101.

60.

Kondziolka

Steinberg

Cullen

McGrogan

. Evaluation of surgical techniques for neuronal cell transplantation used in patients with stroke. Cell Transplant 2004; 13: 749–754.

61.

Kondziolka

Gobbel

Fellows-Mayle

Chang

Uram

. Injection parameters affect cell viability and implant volumes in automated cell delivery for the brain. Cell Transplant 2011; 20: 1901–1906.

62.

Raymer

Beeson

Holland

Kendall

Maher

Martin

et al.

Translational research in aphasia: from neuroscience to neurorehabilitation. J Speech Lang Hear Res 2008; 51: S259–S275.

63.

Hubbard

Parsons

Neilson

Carey

. Task-specific training: evidence for and translation to clinical practice. Occup Ther Int 2009; 16: 175–189.

64.

McDonnell

Hillier

. P26-3 Use of neurophysiological outcome measures to evaluate function following stroke. Clin Neurophysiol 2010; 121: S257–S258.

65.

Carey

Seitz

Parsons

Levi

Farquharson

Tournier

J-D

et al.

Beyond the lesion: neuroimaging foundations for post-stroke recovery. Future Neurol 2013; 8: 507–527.

66.

Farquharson

Tournier

Calamante

Fabinyi

Schneider-Kolsky

Jackson

et al.

White matter fiber tractography: why we need to move beyond DTI. J Neurosurg 2013; 118: 1367–1377.

67.

Naumova

Modo

Moore

Murry

Frank

. Clinical imaging in regenerative medicine. Nat Biotechnol 2014; 32: 804–818.

68.

Meltzer

Kondziolka

Villemagne

Wechsler

Goldstein

Thulborn

et al.

Serial [18F] fluorodeoxyglucose positron emission tomography after human neuronal implantation for stroke. Neurosurgery 2001; 49: 586–591. (discussion 91–92).

69.

Vincent

Desrosiers

Landreville

Demers

. Burden of caregivers of people with stroke: evolution and predictors. Cerebrovasc Dis 2009; 27: 456–464.

70.

Gloede

Halbach

Thrift

Dewey

Pfaff

Cadilhac

. Long-term costs of stroke using 10-year longitudinal data from the North East Melbourne Stroke Incidence Study. Stroke 2014; 45: 3389–3394.